<p>因塞特医疗（NASDAQ:INCY - 获取免费报告）于周二公布了季度财报。这家生物制药公司报告本季度每股收益为 1.80 美元，低于分析师一致预期的 1.96 美元，差距为 0.16 美元，FiscalAI 报道。因塞特医疗的净利润率为 24.69%，股本回报率为 26.56%。该公司本季度的收入为 15.1 亿美元，而分析师预期为 13.5 亿美元。</p>
<h2>因塞特医疗股价上涨 0.6%</h2>
<ul>
<li>因塞特医疗能否实现 447% 的每股收益预期和管道热度？</li>
</ul>
<p>INCY 股票周二开盘价为 109.03 美元。该公司的市值为 214 亿美元，市盈率为 18.26，市盈增长比率为 0.65，贝塔值为 0.82。因塞特医疗的 12 个月低点为 53.56 美元，12 个月高点为 112.29 美元。该公司的速动比率为 3.13，流动比率为 3.20，债务股本比率为 0.01。该公司的 50 日移动平均价格为 101.83 美元，200 日移动平均价格为 93.57 美元。</p>
<h2>分析师设定新目标价</h2>
<p>几家研究公司对 INCY 发表了评论。富国银行重申了 “持平” 评级，并在 1 月 20 日的报告中将因塞特医疗的目标价下调至 107.00 美元（之前为 116.00 美元）。Truist Financial 在 12 月 24 日的研究报告中设定了因塞特医疗的目标价为 103.00 美元。HC Wainwright 在 2 月 5 日的研究报告中开始覆盖因塞特医疗，给予 “买入” 评级，并设定目标价为 135.00 美元。Guggenheim 在 11 月 3 日的研究报告中将因塞特医疗的评级从 “中性” 上调至 “买入”，并设定目标价为 125.00 美元。最后，Weiss Ratings 在 1 月 22 日的研究报告中重申了因塞特医疗的 “持有（c+）” 评级。九位分析师给予该股票 “买入” 评级，十二位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，因塞特医疗的共识评级为 “持有”，共识目标价为 103.29 美元。</p>
<ul>
<li>2024 年盈利增长的 5 只顶级医疗股</li>
</ul>
<p><strong>查看我们对 INCY 的最新股票分析</strong></p>
<h2>内部活动</h2>
<p>在其他新闻中，执行副总裁 Steven H. Stein 于 12 月 2 日的交易中出售了 20,105 股因塞特医疗股票。股票以平均价格 102.51 美元出售，总价值为 2,060,963.55 美元。交易完成后，该执行副总裁持有 63,129 股公司股票，价值约为 6,471,353.79 美元。此次交易使其持股减少了 24.15%。该交易已在 SEC 的法律文件中披露，您可以通过此链接访问。此外，执行副总裁 Michael James Morrissey 于 12 月 17 日的交易中出售了 4,323 股该股票。该股票以平均价格 97.26 美元出售，总价值为 420,454.98 美元。出售后，该执行副总裁持有 27,507 股公司股票，价值约为 2,675,330.82 美元。此次交易使其持股减少了 13.58%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士出售了 95,225 股公司股票，价值 9,519,745 美元。公司内部人士持有公司股票的 17.80%。</p>
<h2>因塞特医疗的机构交易</h2>
<ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
<p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。MUFG 证券 EMEA plc 在第二季度新建了因塞特医疗的持仓，价值约 32,000 美元。CYBER HORNET ETFs LLC 在第二季度购买了因塞特医疗的股份，价值约 33,000 美元。Geneos Wealth Management Inc.在第一季度将其在因塞特医疗的持仓提高了 350.0%。Geneos Wealth Management Inc.现在持有 756 股该生物制药公司的股票，价值 46,000 美元，此前在上个季度购买了 588 股。CIBC 私人财富集团在第三季度将其在因塞特医疗的持仓增加了 153.8%。CIBC 私人财富集团现在持有 726 股该生物制药公司的股票，价值 62,000 美元，此前在上个季度购买了 440 股。最后，Brown Brothers Harriman &amp; Co.在第三季度将其在因塞特医疗的持仓增加了 43.5%。Brown Brothers Harriman &amp; Co.现在持有 818 股该生物制药公司的股票，价值 69,000 美元，此前在上个季度购买了 248 股。目前 96.97% 的股票由机构投资者和对冲基金持有。</p>
<h2>因塞特医疗公司简介</h2>
<p>（获取免费报告）</p>
<p>因塞特医疗公司是一家总部位于特拉华州威尔明顿的生物制药公司，专注于肿瘤学和炎症领域新疗法的发现、开发和商业化。自 2002 年成立以来，因塞特医疗已从一家小型研究机构发展成为一家全球企业，推进一系列内部开发和合作的资产。该公司的研发工作集中在小分子药物和生物制剂上，这些药物和生物制剂调节与癌症、自身免疫疾病和罕见疾病相关的关键信号通路。</p>
<p>该公司的旗舰产品是 Jakafi®（鲁索替尼），这是一种已获批准用于治疗骨髓纤维化和真性红细胞增多症的 Janus 激酶（JAK）抑制剂。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过因塞特医疗</li>
<li>没有人谈论的买入狂潮</li>
<li>如何每周收集 500-800 美元（黑石的系统）</li>
<li>特朗普的人工智能秘密：比英伟达快 100 倍</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>你的银行账户不再安全</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Incyte 吗？</h2>
<p>在考虑 Incyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Incyte 并不在名单上。</p>
<p>虽然 Incyte 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普生物技术 ETF - SPDR

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

<p>因塞特医疗 (NASDAQ:INCY) 报告的季度每股收益为 $1.80，低于预期 $0.16。该公司实现收入 $15.1 亿，超出预期的 $13.5 亿。因塞特医疗的净利润率为 24.69%，股本回报率为 26.56%。分析师对该股票的评级不一，普遍目标价为 $103.29。近期内部交易中，公司的高管进行了大量股票出售。机构投资者也调整了在该公司的持仓，反映出对因塞特医疗业绩和前景的持续关注</p>

<p>Incyte (NASDAQ:INCY - Get Free Report) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $1.80 EPS for the quarter, missing analysts' consensus estimates of $1.96 by ($0.16), FiscalAI reports. Incyte had a net margin of 24.69% and a return on equity of 26.56%. The company had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.35 billion.</p>
<div class="lb-trans"><p>因塞特医疗（NASDAQ:INCY - 获取免费报告）于周二公布了季度财报。这家生物制药公司报告本季度每股收益为 1.80 美元，低于分析师一致预期的 1.96 美元，差距为 0.16 美元，FiscalAI 报道。因塞特医疗的净利润率为 24.69%，股本回报率为 26.56%。该公司本季度的收入为 15.1 亿美元，而分析师预期为 13.5 亿美元。</p>
</div><h2>Incyte Trading Up 0.6%</h2>
<div class="lb-trans"><h2>因塞特医疗股价上涨 0.6%</h2>
</div><ul>
<li>Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>因塞特医疗能否实现 447% 的每股收益预期和管道热度？</li>
</ul>
</div><p>Shares of INCY stock opened at $109.03 on Tuesday. The company has a market capitalization of $21.40 billion, a P/E ratio of 18.26, a P/E/G ratio of 0.65 and a beta of 0.82. Incyte has a 12-month low of $53.56 and a 12-month high of $112.29. The company has a quick ratio of 3.13, a current ratio of 3.20 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $101.83 and a 200 day moving average price of $93.57.</p>
<div class="lb-trans"><p>INCY 股票周二开盘价为 109.03 美元。该公司的市值为 214 亿美元，市盈率为 18.26，市盈增长比率为 0.65，贝塔值为 0.82。因塞特医疗的 12 个月低点为 53.56 美元，12 个月高点为 112.29 美元。该公司的速动比率为 3.13，流动比率为 3.20，债务股本比率为 0.01。该公司的 50 日移动平均价格为 101.83 美元，200 日移动平均价格为 93.57 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research firms have commented on INCY. Wells Fargo &amp; Company reaffirmed an &#34;equal weight&#34; rating and issued a $107.00 price target (down previously from $116.00) on shares of Incyte in a report on Tuesday, January 20th. Truist Financial set a $103.00 price objective on Incyte in a research report on Wednesday, December 24th. HC Wainwright began coverage on Incyte in a research note on Thursday, February 5th. They issued a &#34;buy&#34; rating and a $135.00 target price for the company. Guggenheim upgraded shares of Incyte from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $125.00 price target on the stock in a research note on Monday, November 3rd. Finally, Weiss Ratings restated a &#34;hold (c+)&#34; rating on shares of Incyte in a research note on Thursday, January 22nd. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Incyte has a consensus rating of &#34;Hold&#34; and a consensus price target of $103.29.</p>
<div class="lb-trans"><p>几家研究公司对 INCY 发表了评论。富国银行重申了 “持平” 评级，并在 1 月 20 日的报告中将因塞特医疗的目标价下调至 107.00 美元（之前为 116.00 美元）。Truist Financial 在 12 月 24 日的研究报告中设定了因塞特医疗的目标价为 103.00 美元。HC Wainwright 在 2 月 5 日的研究报告中开始覆盖因塞特医疗，给予 “买入” 评级，并设定目标价为 135.00 美元。Guggenheim 在 11 月 3 日的研究报告中将因塞特医疗的评级从 “中性” 上调至 “买入”，并设定目标价为 125.00 美元。最后，Weiss Ratings 在 1 月 22 日的研究报告中重申了因塞特医疗的 “持有（c+）” 评级。九位分析师给予该股票 “买入” 评级，十二位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，因塞特医疗的共识评级为 “持有”，共识目标价为 103.29 美元。</p>
</div><ul>
<li>5 top healthcare stocks for earnings growth in 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年盈利增长的 5 只顶级医疗股</li>
</ul>
</div><p><strong>View Our Latest Stock Analysis on INCY</strong></p>
<div class="lb-trans"><p><strong>查看我们对 INCY 的最新股票分析</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, EVP Steven H. Stein sold 20,105 shares of Incyte stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $102.51, for a total value of $2,060,963.55. Following the completion of the transaction, the executive vice president owned 63,129 shares in the company, valued at approximately $6,471,353.79. The trade was a 24.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael James Morrissey sold 4,323 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $97.26, for a total value of $420,454.98. Following the sale, the executive vice president owned 27,507 shares in the company, valued at approximately $2,675,330.82. This trade represents a 13.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 95,225 shares of company stock worth $9,519,745. Corporate insiders own 17.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Steven H. Stein 于 12 月 2 日的交易中出售了 20,105 股因塞特医疗股票。股票以平均价格 102.51 美元出售，总价值为 2,060,963.55 美元。交易完成后，该执行副总裁持有 63,129 股公司股票，价值约为 6,471,353.79 美元。此次交易使其持股减少了 24.15%。该交易已在 SEC 的法律文件中披露，您可以通过此链接访问。此外，执行副总裁 Michael James Morrissey 于 12 月 17 日的交易中出售了 4,323 股该股票。该股票以平均价格 97.26 美元出售，总价值为 420,454.98 美元。出售后，该执行副总裁持有 27,507 股公司股票，价值约为 2,675,330.82 美元。此次交易使其持股减少了 13.58%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士出售了 95,225 股公司股票，价值 9,519,745 美元。公司内部人士持有公司股票的 17.80%。</p>
</div><h2>Institutional Trading of Incyte</h2>
<div class="lb-trans"><h2>因塞特医疗的机构交易</h2>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. MUFG Securities EMEA plc acquired a new position in Incyte during the 2nd quarter worth about $32,000. CYBER HORNET ETFs LLC bought a new position in shares of Incyte in the second quarter worth about $33,000. Geneos Wealth Management Inc. lifted its position in shares of Incyte by 350.0% during the first quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company's stock worth $46,000 after purchasing an additional 588 shares in the last quarter. CIBC Private Wealth Group LLC grew its stake in shares of Incyte by 153.8% during the third quarter. CIBC Private Wealth Group LLC now owns 726 shares of the biopharmaceutical company's stock valued at $62,000 after purchasing an additional 440 shares during the last quarter. Finally, Brown Brothers Harriman &amp; Co. increased its holdings in shares of Incyte by 43.5% in the third quarter. Brown Brothers Harriman &amp; Co. now owns 818 shares of the biopharmaceutical company's stock valued at $69,000 after purchasing an additional 248 shares in the last quarter. 96.97% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。MUFG 证券 EMEA plc 在第二季度新建了因塞特医疗的持仓，价值约 32,000 美元。CYBER HORNET ETFs LLC 在第二季度购买了因塞特医疗的股份，价值约 33,000 美元。Geneos Wealth Management Inc.在第一季度将其在因塞特医疗的持仓提高了 350.0%。Geneos Wealth Management Inc.现在持有 756 股该生物制药公司的股票，价值 46,000 美元，此前在上个季度购买了 588 股。CIBC 私人财富集团在第三季度将其在因塞特医疗的持仓增加了 153.8%。CIBC 私人财富集团现在持有 726 股该生物制药公司的股票，价值 62,000 美元，此前在上个季度购买了 440 股。最后，Brown Brothers Harriman &amp; Co.在第三季度将其在因塞特医疗的持仓增加了 43.5%。Brown Brothers Harriman &amp; Co.现在持有 818 股该生物制药公司的股票，价值 69,000 美元，此前在上个季度购买了 248 股。目前 96.97% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Incyte Company Profile</h2>
<div class="lb-trans"><h2>因塞特医疗公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.</p>
<div class="lb-trans"><p>因塞特医疗公司是一家总部位于特拉华州威尔明顿的生物制药公司，专注于肿瘤学和炎症领域新疗法的发现、开发和商业化。自 2002 年成立以来，因塞特医疗已从一家小型研究机构发展成为一家全球企业，推进一系列内部开发和合作的资产。该公司的研发工作集中在小分子药物和生物制剂上，这些药物和生物制剂调节与癌症、自身免疫疾病和罕见疾病相关的关键信号通路。</p>
</div><p>The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.</p>
<div class="lb-trans"><p>该公司的旗舰产品是 Jakafi®（鲁索替尼），这是一种已获批准用于治疗骨髓纤维化和真性红细胞增多症的 Janus 激酶（JAK）抑制剂。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Incyte</li>
<li>The buying spree that no one is talking about</li>
<li>How to collect $500-$800 weekly (BlackRock's system)</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Your Bank Account Is No Longer Safe</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过因塞特医疗</li>
<li>没有人谈论的买入狂潮</li>
<li>如何每周收集 500-800 美元（黑石的系统）</li>
<li>特朗普的人工智能秘密：比英伟达快 100 倍</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>你的银行账户不再安全</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=INCY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Incyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Incyte 吗？</h2>
</div><p>Before you consider Incyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Incyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Incyte 并不在名单上。</p>
</div><p>While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Incyte 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Incyte (NASDAQ:INCY) Posts Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Market Beat

美国制药 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

因塞特医疗

医药突破 ETF - ALPS

标普生物技术 3 倍做空 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

因塞特医疗 (NASDAQ:INCY) 公布季度财报，每股收益比预期低 0.16 美元